Myth: Once You Start Immunotherapy, You Can Never Stop

No. Immunotherapy is not automatically a lifelong treatment the way some patients assume. Many checkpoint inhibitor regimens studied by NCCN and ASCO are designed with a maximum planned duration — commonly around two years of maintenance dosing — after which treatment stops if the cancer is responding well.

This matters because believing immunotherapy is a lifelong commitment can make some patients hesitate to even start treatment, when in fact most protocols are time-limited from the outset, with the stopping point discussed as part of the original treatment plan, not decided later as an afterthought.

Some situations do call for longer, more open-ended treatment — for example, if scans show a slow but real response that hasn't plateaued yet, or a cancer type where longer maintenance dosing is the studied standard. This is decided case-by-case by your oncology team, not assumed as a blanket rule for everyone.

The idea probably comes from mixing immunotherapy up with other cancer treatments that genuinely are open-ended, such as hormone therapy for breast or prostate cancer, or ongoing maintenance chemotherapy, both of which can continue for years. Because immunotherapy is also given repeatedly, over months, it's easy to assume it follows the same indefinite pattern.

The word "immunotherapy" itself, and phrases like "boosting the immune system," also sound like something ongoing and permanent by nature — closer to how people think about diet or exercise — rather than a precise, time-limited drug protocol with a defined endpoint written into the treatment plan from day one.

• Treatment-free interval — the period after stopping during which many patients continue to do well without further immunotherapy doses.
• Durable response — a response that lasts long after treatment ends, sometimes for years, tracked in published follow-up from major trials.
• Relapse after stopping — some patients' cancer does return after stopping, which is why scans and check-ins continue on schedule even after the last dose.
• Retreatment — if the cancer returns, restarting the same or a related immunotherapy is often considered, depending on the individual case.

Which of these applies to you depends on your specific cancer, how it responded, and how long you were treated — something only your oncology team can assess from your own scans and reports.

• Myth: Immunotherapy Is Only for the Rich — another myth about access, not medicine, that stops families from even asking about it.
• Miracle Cure Stories on Social Media: How to Read Them — the opposite distortion: stories that overpromise instead of overwarn, and how to read them sensibly.
• Myth: Immunotherapy Makes the Cancer Spread Faster — a fear-based myth worth clearing up before it changes a treatment decision.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through immunotherapy, from candidacy to stopping and follow-up care.

This page is for general information and does not replace a consultation. If you're weighing how long your own treatment should continue, discuss it directly with your oncology team.

Thousands of families have asked us this same question

Understanding when and how immunotherapy can stop is the first step to making a confident decision about starting it.